Table III.
Patient demographic and baseline disease characteristics during the antiviral phase.
| Patient demographics | Antiviral phase N=41 |
|---|---|
| Age (years), median (range) | 61 (31–72) |
| Sex, n (%) | |
| Female | 28 (68) |
| Male | 13 (32) |
| Body mass index (kg/m2), mean ± SD | 23.2±3.6 |
| Diagnosis, n (%) | |
| Chronic hepatitis | 22 (54) |
| Cirrhosis | 19 (46) |
| HCV genotype, n (%) | |
| 1a | 0 |
| 1b | 31 (76) |
| 2a | 6 (15) |
| 2b | 3 (7) |
| Othera | 1 (2) |
| Child-Pugh classification | |
| A (score 5–6) | 40 (98) |
| B (Score 7–9) | 1 (2) |
| Baseline platelet counts, median (range) | 63,000 |
| (37,000–78,000) | |
| HCV RNA (Log IU/ml), mean ± SD | 6.4±0.7 |
| ALT (IU/l), mean ± SD | 82.0±48.0 |
a
This patient was infected with HCV serogroup 2. ALT, alanine transaminase; HCV, hepatitis c virus; SD, standard deviation.